Stereotactic radiation boost before chemoradiotherapy for stage iii lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a short, high-dose blast of radiation to the main tumor before standard chemotherapy and radiation can help people with locally advanced lung cancer. It aims to improve how well the cancer is controlled while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have non-small cell lung cancer (NSCLC) that cannot be removed with surgery and has not spread to distant parts of the body
- Not have certain genetic changes (driver mutations) in the cancer
- Be in good physical condition (able to carry out daily activities with minimal help)
- Have a clear tumor in the lung that can be safely targeted with radiation
- Be willing to participate and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial is testing whether giving focused radiation therapy to the main lung tumor, in addition to standard treatments like targeted therapy or chemo-immunotherapy, can help people with advanced lung cancer that has spread to many places. The goal is to see if adding this radiation can improve outcomes without causing too many side effects.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.